INTRODUCTION
============

Cancer has been the leading cause of death in Korea since 1983 and is the most burdensome disease \[[@b9-jkns-2017-0304]\]. Metastatic spine tumors have become clinically important due to the availability of improved diagnostic tools and increases in survival periods of cancer patients \[[@b10-jkns-2017-0304]\].

We previously reported nationwide studies pertaining to the characteristics, healthcare utilization rates and survival periods of metastatic spine tumor patients \[[@b6-jkns-2017-0304],[@b8-jkns-2017-0304]\]. We have also investigated the current nationwide state of stereotactic radiosurgery in spine metastasis \[[@b5-jkns-2017-0304]\]. However, there has been no nationwide study about the different surgical methods used to treat metastatic spine tumors.

Nationwide studies are less subject to selection or non-response bias than case-series studies, implying that their analyses can have high statistical power \[[@b4-jkns-2017-0304]\]. The aim of this nationwide study was to analyze the current state and survival rates of patients with newly diagnosed metastatic spine tumors according to different surgical methods.

MATERIALS AND METHODS
=====================

Data source
-----------

All Korean citizens are beneficiaries of the Korean National Health Insurance System \[[@b3-jkns-2017-0304]\], and nationwide inpatient and outpatient data on disease and services (procedures and operations) are coded and registered in the Korean Health Insurance Review and Assessment Service (HIRA) database, thus enabling the undertaking of population-based studies \[[@b3-jkns-2017-0304]\]. The HIRA database is a "fee-for-service" system. Disease codes used in the database are standardized according to the Korean Classification of Disease, 4th version, which follows the International Classification of Disease, 10th version (ICD-10) \[[@b3-jkns-2017-0304]\]. This study was approved by the institutional review boards (1308-013-510).

Patient population
------------------

Patients over 20 years old with metastatic spine tumors were identified from the HIRA database between 2010 and 2015. A multidisciplinary panel consisting of spine surgeons, epidemiologists, and a radiation oncologist identified patients with newly diagnosed metastatic spine tumors. Disagreements were resolved by consensus after discussion \[[@b5-jkns-2017-0304],[@b6-jkns-2017-0304],[@b8-jkns-2017-0304]\].

A newly diagnosed metastatic spine tumor was defined by applying the following criteria; 1) presence of an ICD-10 code for metastatic spine tumor, 2) spine MRI performed within 1 year after the ICD-10 code assessment, 3) no previous identical tumor code history within 1 year, and 4) patients who underwent surgery. ICD-10 codes for metastatic spine tumors were C79.5 (secondary malignant neoplasm of the bone and marrow) and M49.50 (metastatic fracture of the vertebra, multiple sites in the spine).

We categorized the surgeries into three types and placed patients into three surgical groups. These were the fusion, decompression, and vertebroplasty groups. The vertebroplasty group included those who had percutaneous vertebroplasty, percutaneous balloon kyphoplasty, and percutaneous sacroplasty. Fusion surgery was defined as an operation with instrumentation. Decompression surgery was defined as an operation without instrumentation.

We also differentiated the primary tumor site into the lung, liver & biliary, breast, colon, stomach, prostate, rectum, pancreas, plasma cell, kidney, and others. For each surgical method, we analyzed the corresponding group's age, sex, health insurance type, co-morbidities, and numbers of patients for each primary tumor site. For comorbidities, we referred to the Charlson Comorbidity Index \[[@b1-jkns-2017-0304],[@b2-jkns-2017-0304]\].

In our assessment of survival rates, we analyzed patients with metastatic spine tumors diagnosed during 2011 and 2012. This allowed us to obtain 3-year follow-up data for analysis. Comparative survival analyses were performed according to three surgical methods.

Death was deemed to have occurred when a patient with a metastatic spine tumor did not use any medical service for 6 consecutive months. The date of death in our study was determined by the last date of medical service usage. The survival period was calculated from the date of the first diagnosis of spine metastasis. We used this definition of death after verifying that data from several different durations other than 6 months produced similar results \[[@b5-jkns-2017-0304]-[@b8-jkns-2017-0304]\].

Statistical analysis
--------------------

The numbers of patients according to age at diagnosis, sex, year of diagnosis, health insurance type, and comorbidities were calculated for each of the three surgical methods. A logistic regression analysis was conducted in each case to evaluate incidence rates by age and diagnosis year. Differences in incidence rates according to sex, health insurance type, and comorbidities were assessed using chi-square tests. The differences among the three surgical methods were evaluated by using analysis of variance (ANOVA).

Survival rates from metastatic spine tumors for each surgical method were compared using the Kaplan Meier method and with Cox proportional hazard regressions. A two-tailed *p* value \<0.05 was considered indicative of a significant difference. For statistical analyses, SAS software (version 9.1.3; SAS Institute, Inc., Cary, NC, USA) was used. The statistical tests used in this study were counseled by the Medical Research Collaborating Center (2014-0162).

Results
=======

Characteristics of metastatic spine tumor patients who underwent surgery
------------------------------------------------------------------------

The overall number of patients who underwent surgery was 1677 during the study period ([Table 1](#t1-jkns-2017-0304){ref-type="table"}). The number of metastatic spine tumor patients among the seven age groups ranged from 13 (0.8%) to 486 (29%) with the 60--69 years age group having the highest number. The number of metastatic spine tumor patients who underwent surgery increased with age except over 80 years old group (*p*\<0.001, [Table 1](#t1-jkns-2017-0304){ref-type="table"}).

Characteristics of metastatic spine tumor patients according to the surgical methods
------------------------------------------------------------------------------------

Among the 1677 patients who had an operation, 823 patients were treated by fusion surgery, 141 patients were treated by decompression, and 713 patients underwent a vertebroplasty ([Table 1](#t1-jkns-2017-0304){ref-type="table"}). When the three surgical methods were stratified by patient age, the 60--69 years age group had the highest number in fusion and decompression (30.4% and 32.6%). In contrast, the 70--79 years age group had the highest number for vertebroplasty (36.2%, [Table 1](#t1-jkns-2017-0304){ref-type="table"}). There were significantly more male patients than female patients in the fusion and decompression groups (*p*=0.018 and 0.001, respectively, [Table 1](#t1-jkns-2017-0304){ref-type="table"}).

The number of metastatic spine tumor patients significantly increased from 2011 to 2012 in the fusion group (*p*=0.023). In contrast, the number of metastatic spine tumor patients significantly decreased in the decompression group (*p*=0.037, [Table 1](#t1-jkns-2017-0304){ref-type="table"}).

Comparison among different surgeries according to the primary tumor site
------------------------------------------------------------------------

The numbers of patients who underwent surgery according to the primary tumor site were as follows : 314 in lung (18.7%), 166 in liver & biliary (9.9%), 134 in prostate (8.0%), 85 in plasma cell (5.1%), 79 in breast (4.7%), 74 in colon (4.4%), 59 in stomach (3.5%), 58 in kidney (3.5%), 57 in rectum (3.4%), and 43 in pancreas (2.6%, [Table 2](#t2-jkns-2017-0304){ref-type="table"}).

When the 3 surgical methods were stratified according to primary tumor site, the number of patients who underwent fusion was significantly higher compared to those who used the other methods in the liver & biliary, breast, and kidney (*p*\<0.0001, \<0.0001, \<0.0001, respectively; [Table 2](#t2-jkns-2017-0304){ref-type="table"}). In contrast, the number of patients who underwent vertebroplasty was higher than those who underwent other methods in lung, stomach, rectum, and plasma cell (*p*=0.0032, 0.042, \<0.0001, \<0.0001, respectively; [Table 2](#t2-jkns-2017-0304){ref-type="table"}). For each primary tumor site, decompression was the least common modality ([Table 2](#t2-jkns-2017-0304){ref-type="table"}).

Survival rate according to the surgical method
----------------------------------------------

The median survival rates for each surgical method were 228 days for fusion surgery, 249 days for decompression, and 154 days for vertebroplasty. Overall survival rates were 88.3%, 73.0%, 59.3%, and 42.6% at 1, 3, 6, and 12 months, respectively. Actuarial survival rates in patients who had fusion surgery were 89.8%, 72.9%, 56.2%, and 39.4% at 1, 3, 6, and 12 months, respectively. In the decompression group, survival rates were 85.0%, 71.9%, 56.7%, and 44.6% at 1, 3, 6, and 12 months, respectively. In the vertebroplasty group, survival rates were 85.1%, 64.4%, 47.3%, and 35.1% at 1, 3, 6, and 12 months, respectively ([Fig. 1](#f1-jkns-2017-0304){ref-type="fig"}). The survival graphs for fusion and decompression crossed each other at postoperative 220 days ([Fig. 1](#f1-jkns-2017-0304){ref-type="fig"}).

The Cox regression model results showed that increasing age, male sex, and comorbidities were significant negative factors affecting the survival rate in metastatic spine tumor patients (*p*\<0.0001, \<0.0001, \<0.0001, respectively; [Table 3](#t3-jkns-2017-0304){ref-type="table"}). However, there were no significant difference in patient survival rates among the three differentiated surgical methods ([Table 3](#t3-jkns-2017-0304){ref-type="table"}).

Discussion
==========

Characteristics of metastatic spine tumor patients according to surgery
-----------------------------------------------------------------------

The number of metastatic spine tumor patients who underwent surgery increased with patient age in this study. The peak number for those patients was found in the group aged 60--69 years ([Table 1](#t1-jkns-2017-0304){ref-type="table"}). These results were similar to those of previous studies that were conducted with overall metastatic spine tumor patients \[[@b6-jkns-2017-0304],[@b8-jkns-2017-0304],[@b10-jkns-2017-0304]\].

Additionally, the number of metastatic spine tumor patients increased significantly as the number of comorbidities increased (*p*\<0.001, [Table 1](#t1-jkns-2017-0304){ref-type="table"}). This result was also in accordance with the result from a previous study \[[@b6-jkns-2017-0304]\].

The number of patients who underwent fusion surgery significantly increased during the study period, whereas significantly fewer underwent decompression surgery. Further studies are warranted with longer investigation periods to confirm this trend.

Characteristics of metastatic spine tumor patients who underwent surgery according to the primary tumor site
------------------------------------------------------------------------------------------------------------

In our study, the three most prevalent primary tumor sites were the lung, breast, and liver & biliary. On the other hand, the three most prevalent primary tumor sites of patients who underwent surgery were the lung, liver & biliary, and prostate. Based on these patterns, patients whose primary tumor site was the prostate had a high tendency to undergo surgery. In contrast, patients whose primary tumor site was the breast showed a low tendency to undergo surgery.

Survival rate according to the surgical method
----------------------------------------------

In this study, the survival graphs for fusion and decompression crossed each other at postoperative 220 days, as noted earlier. The prognosis of the fusion surgery group was better than that of the decompression group for the less than postoperative 220 days population. We can infer that the prognosis of the fusion surgery group was better than that of the decompression group for the less than postoperative 220 days population. When we consider that the median overall survival period was 191 days in spine metastasis \[[@b6-jkns-2017-0304]\], most patients with a good prognosis showed a tendency to undergo fusion surgery as opposed to decompression surgery.

The lowest median survival period among the three surgical methods was 154 days in the vertebroplasty group. Vertebroplasty is a relatively simple procedure that can be performed under local anesthesia. Therefore, patients with a poor prognosis tended to undergo vertebroplasty. However, further studies are needed to uncover the relationship between surgery and patient prognosis.

Limitations
-----------

Several limitations of this study should be noted. First, because this is a nationwide study based on the HIRA database, it could not depict regional variations in disease diagnosis, coding, or reporting, such as differences between those who live in cities and more rural areas. Second, the presence of additional conditions is inevitable when defining spine metastasis and death. As described in our previous study \[[@b8-jkns-2017-0304]\], we investigated the influence of other limiting conditions by comparing the results with hospital record data obtained from a tertiary hospital. In addition, although a multidisciplinary panel consisting of spine surgeons, epidemiologists, and a radiation oncologist reached consensus on a definition of death (a patient with metastatic spine tumor who did not use any medical services for 6 consecutive months), we also compared data from several other durations and verified that the results were similar. Third, due to the basic limit of the HIRA database, we could not provide the information about quality of life or severity of pain. Notwithstanding those limitations, to the best of our knowledge, this is the first nationwide study which focused on surgery in spine metastasis.

Conclusion
==========

For every primary tumor site, decompression was the least common surgical method during the study period. Although the 3 surgical methods did not significantly affect survival periods, patients with a poor prognosis may tend to undergo vertebroplasty.

No potential conflict of interest relevant to this article was reported.

**INFORMED CONSENT**

Informed consent was obtained from all individual participants included in this study.

This research was supported by a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea (grant number: HR16C0002). The authors declare no conflict of interest concerning the materials or methods used in this study or the findings described in this paper. The need for informed consent was waived because the data used consisted of deidentified secondary data released for research purposes which subsequently were analyzed anonymously.

![Kaplan-Meier estimates of overall survival associated with the three different surgical methods in metastatic spine tumor patients.](jkns-2017-0304f1){#f1-jkns-2017-0304}

###### 

Characteristics according to each surgery in metastatic spine tumor, South Korea, 2011--2012

  Characteristic             Total          *p*-value                                                  Surgery       *p*-value                                                  Fusion       *p*-value                                                  Decompression   *p*-value                                                Vertebroplasty   *p*-value
  -------------------------- -------------- ---------------------------------------------------------- ------------- ---------------------------------------------------------- ------------ ---------------------------------------------------------- --------------- -------------------------------------------------------- ---------------- ----------------------------------------------------------
  Total                      13748 (100)                                                               1677 (100)                                                               823 (100)                                                               141 (100)                                                                713 (100)        
  Gender                                    \<0.001^[\*](#tfn1-jkns-2017-0304){ref-type="table-fn"}^                 0.906                                                                   0.018^[\*](#tfn1-jkns-2017-0304){ref-type="table-fn"}^                     0.001\*                                                                   0.125
   Male                      7954 (57.9)                                                               968 (57.7)                                                               499 (60.6)                                                              90 (68.7)                                                                379 (53.2)       
   Female                    5794 (42.1)                                                               709 (42.3)                                                               324 (39.4)                                                              51 (38.9)                                                                334 (46.8)       
  Age at diagnosis (years)                                                                                                                                                                                                                                                                                                                        
   20--29                    144 (1)        \<0.001^[\*](#tfn1-jkns-2017-0304){ref-type="table-fn"}^   13 (0.8)      \<0.001^[\*](#tfn1-jkns-2017-0304){ref-type="table-fn"}^   9 (1.1)      \<0.001^[\*](#tfn1-jkns-2017-0304){ref-type="table-fn"}^   4 (2.8)         0.06                                                     0 (0)            \<0.001^[\*](#tfn1-jkns-2017-0304){ref-type="table-fn"}^
   30--39                    527 (3.8)                                                                 50 (3)                                                                   34 (4.1)                                                                5 (3.5)                                                                  11 (1.5)         
   40--49                    1592 (11.6)                                                               148 (8.8)                                                                90 (10.9)                                                               12 (8.5)                                                                 46 (6.5)         
   50--59                    3391 (24.7)                                                               369 (22)                                                                 238 (28.9)                                                              31 (22)                                                                  100 (14)         
   60--69                    3764 (27.4)                                                               486 (29)                                                                 250 (30.4)                                                              46 (32.6)                                                                190 (26.6)       
   70--79                    3453 (25.1)                                                               481 (28.7)                                                               186 (22.6)                                                              37 (26.2)                                                                258 (36.2)       
   ≥80                       877 (6.4)                                                                 130 (7.8)                                                                16 (1.9)                                                                6 (4.3)                                                                  108 (15.1)       
  Diagnosis year                            0.545                                                                    0.52                                                                    0.023^[\*](#tfn1-jkns-2017-0304){ref-type="table-fn"}^                     0.037^[\*](#tfn1-jkns-2017-0304){ref-type="table-fn"}^                    0.715
   2011                      6736 (49)                                                                 834 (49.7)                                                               386 (46.9)                                                              82 (58.2)                                                                336 (47.1)       
   2012                      7012 (51)                                                                 843 (50.3)                                                               437 (53.1)                                                              59 (41.8)                                                                347 (48.7)       
  Health                                                                                                                                                                                                                                                                                                                                          
   insurance type                           \<0.001^[\*](#tfn1-jkns-2017-0304){ref-type="table-fn"}^                 0.522                                                                   0.183                                                                      0.221                                                                     0.509
   Medicare                  12854 (93.5)                                                              1574 (93.9)                                                              779 (94.7)                                                              129 (91.5)                                                               666 (93.4)       
   Medicaid                  894 (6.5)                                                                 103 (6.1)                                                                44 (5.3)                                                                12 (8.5)                                                                 47 (6.6)         
  CCI                                       \<0.001^[\*](#tfn1-jkns-2017-0304){ref-type="table-fn"}^                 \<0.001^[\*](#tfn1-jkns-2017-0304){ref-type="table-fn"}^                0.041^[\*](#tfn1-jkns-2017-0304){ref-type="table-fn"}^                     0.088                                                                     0.015^[\*](#tfn1-jkns-2017-0304){ref-type="table-fn"}^
   0                         2690 (19.6)                                                               431 (25.7)                                                               234 (28.4)                                                              42 (29.8)                                                                155 (21.7)       
   1                         1151 (8.4)                                                                184 (11)                                                                 94 (11.4)                                                               7 (5)                                                                    83 (11.6)        
   2                         5858 (42.6)                                                               621 (37)                                                                 296 (36)                                                                51 (36.2)                                                                274 (38.4)       
   ≥3                        4049 (29.5)                                                               441 (26.3)                                                               199 (24.2)                                                              41 (29.1)                                                                201 (28.2)       

Values are presented as number (%).

Indicates statistical significance.

CCI : Charlson Comorbidity Index

###### 

Comparison among different surgeries in each primary tumor site, South Korea, 2011--2012

  Original tumor site   Total           Surgery        Fusion        Decompression   Vertebroplasty   *p*-value
  --------------------- --------------- -------------- ------------- --------------- ---------------- ------------
  Total                 13748 (100.0)   1677 (100.0)   823 (100.0)   141 (100.0)     713 (100.0)      
   Lung                 2974 (21.6)     314 (18.7)     145 (17.6)    20 (14.2)       149 (20.9)       0.0032\*
   Liver & biliary      1167 (8.5)      166 (9.9)      108 (13.1)    12 (8.5)        46 (6.5)         \<0.0001\*
   Breast               1207 (8.8)      79 (4.7)       44 (5.3)      5 (3.5)         30 (4.2)         \<0.0001\*
   Colon                537 (3.9)       74 (4.4)       35 (4.3)      7 (5.0)         32 (4.5)         0.6852
   Stomach              577 (4.2)       59 (3.5)       20 (2.4)      4 (2.8)         35 (4.9)         0.042\*
   Prostate             1112 (8.1)      134 (8.0)      62 (7.5)      11 (7.8)        61 (8.6)         0.9035
   Rectum               316 (2.3)       57 (3.4)       16 (1.9)      8 (5.7)         33 (4.6)         \<0.0001\*
   Pancreas             343 (2.5)       43 (2.6)       20 (2.4)      1 (0.7)         22 (3.1)         0.409
   Plasma cell          460 (3.3)       85 (5.1)       30 (3.6)      5 (3.5)         50 (7.0)         \<0.0001\*
   Kidney               287 (2.1)       58 (3.5)       44 (5.3)      5 (3.5)         9 (1.3)          \<0.0001\*
   Others               5922 (43.1)     666 (39.7)     336 (40.8)    55 (39.0)       275 (38.6)       0.022\*

Values are presented as number (%).

Indicates statistical significance

###### 

HR according to various characteristics of spine metastasis patients, 2011--2012

  Characteristic                     HR      95% CI         *p*-value
  ---------------------------------- ------- -------------- ------------
  Male (female ref.)                 1.474   1.416--1.535   \<0.0001\*
  Age                                1.087   1.07--1.104    \<0.0001\*
  Medicaid (medicare ref.)           1.126   1.042--1.216   0.0028\*
  CCI                                1.062   1.042--1.082   \<0.0001\*
  Decompression (no surgery ref.)    0.835   0.683--1.021   0.0788
  Fusion (no surgery ref.)           1.02    0.94--1.106    0.6384
  Vertebroplasty (no surgery ref.)   1.015   0.929--1.108   0.7427

HR : hazard ratio, CI : confidence interval, ref. : reference, CCI : Charlson Comorbidity Index
